Long-acting (LA) implantable drug delivery systems (IDDS) present an effective strategy for managing or preventing chronic conditions through sustained parenteral therapeutic administration, thereby enhancing treatment adherence by minimizing dosing frequency. Currently available drug-releasing implantable devices in the market necessitate surgery for removal and replacement. The ability to refill these implantable devices extends their lifespan and treatment duration. Addressing this concern, Dr. Alessandro Grattoni's laboratory at the Houston Methodist Research Institute has developed a transcutaneously refillable implant (nDS) capable of reloading with solid particles. This implant demonstrates a 1000-fold increase in drug load efficiency compared to implants loaded with saturated liquid solutions.